Introduction
Colonic self-expanding metal stents (SEMS) are the preferred option in palliative, malignant left-sided colonic obstruction1. Caution remains in cases of curative disease with oncological intent often being undetermined at the time of emergency presentation. In simple terms, patients prefer not to have a stoma, and oncologists dread a perforation event.
Aims & Methods
We consider SEMS in all cases of malignant colonic obstruction, including caecal cancers requiring stenting through the ileo-caecal valve. We have collected data over a 15-year period and compare the success, benefit and risks of stenting in the proximal colon to accepted practice for SEMS in the left hemi-colon. Assessment was through recording clinical success, perforation at any time point after stenting, and need for re-intervention. In unresected cases, we compared median stoma-free survival, which we considered would be important to patients. Availability of SEMS is adaptable but not comprehensive in our institution, and are always performed with both colonoscopy and fluoroscopy, and using uncovered stents. We excluded cases where spontaneous perforation had occured at the time of CT and prior to any intervention.
Results
Over 15 years, 301 patients presented with radiologically confirmed malignant colonic obstruction, with a cancer proximal to the splenic flexure in 102 of these cases (33.9%). One third of these proximal cases involved the caecum. Overall 253 (84%) were referred for SEMS. Clinical relief of obstruction by SEMS was achieved in 217 (85.8%) cases, but with lower success in right-sided cancers (79% v 89%, p = 0.039). The reduction in success was predominantly due to failure of colonoscopy to access the proximal colonic stricture. Perforation rate within 30 days of index SEMS was 0.4%. In total 64 patients (21.3%) underwent emergency surgery – 42 as primary management and 22 patients after unsuccessful SEMS, with 93% receiving a stoma. Importantly, no initial surgery occurred in the aftermath of a perforation from an attempt at stenting. In 20 patients (6.6%) colonic obstruction was ultimately managed palliatively, including after unsuccessful SEMS. In the 217 cases of successful SEMS, 42 underwent subsequent resection of their primary colorectal cancer site, with 175 cancers not resected and managed with palliative intention (8.6% remain alive). Death occured within 30 days of palliative stenting in 5.1%. Perforation at any time-point occurred in 2.8% of left-sided cases only. Re-intervention rates (re-stenting or surgery) were lower in right-sided SEMS (8.8% v 20.5%, p = 0.039). Non-colorectal histology was identified in 4% of cases and was associated with inferior success and survival. There was no significant difference in stoma-free survival curves for palliative right and left-sided cancers (median 301 v 243 days, p = 0.61). Lifetime stoma rates in this unresected group was low at 4.6%, and overall 16% of patients survived in excess of 24 months after palliative SEMS.
Conclusion
Right-sided colonic stenting is marginally less successful but still achieves clinical and durable resolution of colonic obstruction in 79% cases, and with no increase in adverse events. Stoma-free survival in unresected cancer is equivalent at 8-10 months and there appears to be a lower rate of re-intervention. We propose that SEMS should be considered with equivalent validity in cases of right-sided colonic obstruction, where there is availability of colonoscopy, fluoroscopy and appropriate expertise.
References
1. van Hooft JE, Veld JV, Arnold D et al. Self-expandable metal stents for obstructing colonic and extracolonic cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2020. Endoscopy 2020; 52: 389-407